As of November 14, 2026, Lyell Immunopharma, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on March 9, 2026 (Form 8-K, March 9, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like Lyell Immunopharma, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Lyell Immunopharma, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-03-09. Every row below is cited to the filing it comes from, and this page adds each new change as Lyell Immunopharma, Inc. files it.
Layoffs on record: about 73 jobs, latest 2025-04-01 (layoff filings and notices).
Also on the record for Lyell Immunopharma, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 10, 2026 | Stake report, Schedule 13G/A, by ARCH Venture Fund IX, L.P. | 17.4% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by James B. Tananbaum | 2.7% of the class | 5%+ stakes | Source |
| June 18, 2026 | Stake report, Schedule 13G/A, by Innovative Cellular Therapeutics Holdings Limited | 12.3% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by ARCH Venture Fund IX, L.P. | 13.9% of the class | 5%+ stakes | Source |
| May 11, 2026 | Stake report, Schedule 13G/A, by MWG Caph Ltd | 4.3% of the class | 5%+ stakes | Source |
| May 8, 2026 | Stake report, Schedule 13G/A, by Explore Investments LLC | 6.6% of the class | 5%+ stakes | Source |
| April 21, 2026 | Stake report, Schedule 13G, by EULER FUND, L.P. | 6.71% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by ARCH Venture Fund IX, L.P. | 13% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by James B. Tananbaum | 7.6% of the class | 5%+ stakes | Source |
| November 13, 2025 | Stake report, Schedule 13G, by Innovative Cellular Therapeutics Holdings Ltd | 9.8% of the class | 5%+ stakes | Source |
| November 12, 2025 | Stake report, Schedule 13G/A, by Newton (PTC) Limited | 3.93% of the class | 5%+ stakes | Source |
| August 19, 2025 | Stake report, Schedule 13G, by Explore Investments LLC | 5.4% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Lyell Immunopharma, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Lyell Immunopharma, Inc. and the records around it.
Lyell Immunopharma, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Who owns it
Companies that share a holder
- Gates Frontier, LLC also filed stake reports on 1 other company: Evolv Technologies Holdings, Inc. (Sep 2025)
- Newton (PTC) Limited also filed stake reports on 1 other company: Figure Technology Solutions, Inc. (Nov 2025)
- ARCH Venture Fund IX, L.P. also filed stake reports on 2 other companies: Vir Biotechnology, Inc. (Nov 2026), Sana Biotechnology, Inc. (Aug 2026)
Watch Lyell Immunopharma, Inc.
Get an email when Lyell Immunopharma, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Lyell Immunopharma, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Lyell Immunopharma, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Lyell Immunopharma, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 13 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-03-09 | Reported | not named in the filing | 8-K, 2026-03-09 |
New leaders reset buying decisions — get the Full Report on Lyell Immunopharma, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Lyell Immunopharma, Inc., with the record behind each one.
Find candidates like senior executive at Lyell Immunopharma, Inc.Every change, in the filing's words
Reported
On March 6, 2026, the Board of Directors of Lyell Immunopharma, Inc. (the "Company") approved the appointment of Smital Shah as the Company's Chief Financial and Business Officer and principal financial officer, effective March 9, 2026.
- Lynn Seely, M.D., the Company's President and Chief Executive Officer, previously served as interim principal financial officer.
- In connection with Ms. Shah's appointment as the Company's Chief Financial and Business Officer, the Company and Ms. Shah entered into an offer letter that governs the terms of Ms. Shah's at-will employment relationship with the Company.
- Pursuant to the offer letter, Ms. Shah is entitled to receive an initial annual base salary of $500,000 and a target annual bonus of up to 50% of her base salary.
- In addition, Ms. Shah will receive a stock option for 140,000 shares of common stock of the Company, with an exercise price equal to the fair market value of the common stock of the Company on the date of grant, to be granted under the Company's 2021 Equity Incentive Plan.
- Twenty-five percent (25%) of the total shares subject to the option will vest on the one-year anniversary of Ms. Shah's employment commencement date and an additional 1/48th of the total shares subject to the option will vest in equal monthly installments thereafter, subject to Ms. Shah remaining an employee of the Company on each applicable vesting date.
Tools for this story
Each opens in a new tab, filled in for Lyell Immunopharma, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
